Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 8/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9460481 | 0.89 | HTR4 (0.61) | HTR4ACHEDRD2DRD4DRD3 | |
| SCHEMBL9460469 | 0.89 | HTR4 (0.61) | HTR4ACHEDRD2DRD4DRD3 | |
| SCHEMBL9460473 | 0.89 | HTR4 (0.61) | HTR4ACHEDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9460956 | 0.88 | HTR4 (0.60) | HTR4ACHEDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9460955 | 0.88 | HTR4 (0.60) | HTR4ACHEDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9460954 | 0.88 | HTR4 (0.60) | HTR4ACHEDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9460967 | 0.88 | MAPK1 (0.59) | HTR4ACHEDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9460964 | 0.88 | MAPK1 (0.59) | HTR4ACHEDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9460962 | 0.88 | MAPK1 (0.59) | HTR4ACHEDRD2DRD4DRD3 | |
| SCHEMBL8052736 | 0.83 | HTR4 (0.52) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956450-B1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | UNIV MUENCHEN TECH (DE) | 2018-07-25 | — | — | EP | claimed |
| US-20150376164-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2015-12-31 | — | — | US | claimed |
| EP-2956450-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | Technische Universität München (DE) | 2015-12-23 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014125084-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | Technische Universität München (DE) | 2014-08-21 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009018169-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005074931-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING (S) -PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376164-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | HTR5A, HTR4, HTR6 | HTR4 2/4885ACHE 196/4885DRD2 32/4885 |
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | OPRM1, OPRD1, OPRK1 | HTR4 171/4885ACHE 395/4885DRD2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.